Pular para o conteúdo
Radio Logo
PodcastsCiênciaBJGP Interviews

BJGP Interviews

The British Journal of General Practice
Último episódio

200 episódios

  • BJGP Interviews

    Making Advice and Guidance work in general practice

    17/11/2026 | 17min
    Today, we’re speaking to Dr Vicki Wesh and Dr Claire Burton about the paper they’ve published here in the BJGP alongside co-first authors Alice Faux-Nightingale and Rosie Harrison.
    Title of paper: Why Primary Care Clinicians use Advice and Guidance: A qualitative study
    Available at: https://doi.org/10.3399/BJGP.2026.0217
    Advice and Guidance (A&G), introduced in 2015, enables primary care clinicians to obtain specialist input for patients within elective care pathways without initiating a formal referral; the proposed 2026/27 GP Contract aims to expand or mandate its use in line with the NHS ten-year plan and strategic efforts to move more care from hospitals into the community.
    • Our findings suggest clinicians decide to engage with A&G when they can expect timely, high-quality responses that support safe management of sometimes clinically complex patients.
    • Primary Care Clinicians are also sensitive to the risks of inappropriate transfer of workload from secondary to primary care, clinical responsibility for conditions traditionally managed in secondary care, and associated costs into primary care, and that these concerns directly influence their willingness to use A&G.
    • Ensuring that electronic A&G systems support transparent, two-way communication and maintain visibility for both primary and secondary care teams may therefore improve usability and sustain clinician engagement.
    Transcript
    This transcript was generated using AI and has not been reviewed for accuracy. Please be aware it may contain errors or omissions.
    Speaker A
    00:00:01.600 - 00:01:03.060
    Hi and welcome to BJGP Interviews.

    I'm Nada Khan and I'm the Senior Research editor here at the bjgp.

    Thanks for listening to today's podcast.

    In today's episode, we're talking to Dr. Vicki Welsh and Dr. Claire Burton about the paper they've published here in the bjgp.

    They've published this alongside co first authors Alice Vo Nightingale and Rosie Harrison, and the paper is titled why Primary Care Clinicians Use Advice and A Qualitative Study.

    So thanks very much for joining me, both of you, and it's a really interesting paper and it's highly topical, I think, in today's primary care setting.

    Just thinking about how we're using advice and guidance and Claire, I wonder if I could just come to you first and I wonder if you could just start by giving us a bit of an overview of what advice and guidance is meant to offer and maybe also just about how you want to explore how primary care clinicians actually use it.

    Speaker B
    00:01:03.300 - 00:02:03.040
    Advice and guidance is essentially a process that allows primary care clinicians, so we use that term inclusively to include GPs, advanced nurse practitioners, physicians, associates and anyone else in the primary care setting who might be using advice and guidance to seek formalised advice from specialists.

    So usually consultants in a secondary care setting around the care of their patients.

    So it doesn't necessitate a formal or full elective referral, but it goes through usually the electronic referral system, which means that the question that is being asked and the response that is being given is formalised and can be fed back to patients and used in the process of care.

    So I suppose, you know, 20 years ago we'd have been picking up the phone or emailing our colleagues, but this has become, since 2015, a more formalised process that can be used as an option when seeking specialist advice.

    Speaker A
    00:02:03.600 - 00:02:11.200
    Yeah.

    And Vicky, you were just going to also tell us a little bit about why you wanted to look at how primary care clinicians actually use it in practice.

    Speaker C
    00:02:11.920 - 00:02:59.720
    So, as gps, Clare and I have had mixed experiences in our own practice of using advice and guidance.

    Sometimes it can be really helpful, sometimes less so.

    And we were aware back in 2022, 23, when we wrote this research project, that advice and guidance was being increasingly used by our specialist colleagues, but there was no real evidence base to support the best use of advice and guidance.

    So we designed this badger study, along with our CO applicants, to develop an evidence base, really, to help us, as an NHS system, make best use of this advice and guidance service.

    Speaker A
    00:03:00.360 - 00:03:33.960
    Yeah, fair enough.

    So in this project you conducted 20 semi structured interviews with primary care clinicians from 20 practices across the Northwest and West Midlands.

    And really, you just explored their experiences of using advice and guidance.

    And I think it's really interesting that your findings suggest that clinicians don't use advice and guidance for every patient or in every situation, really.

    But I wonder what your thoughts were from the interviews about what people thought made it useful and when a direct referral might be more appropriate.

    Speaker B
    00:03:34.840 - 00:03:39.000
    So, again, I just wonder if it might be best to contextualize these interviews.

    Sure,.

    Speaker C
    00:03:39.160 - 00:03:39.640
    Yeah.

    Speaker B
    00:03:39.720 - 00:05:56.320
    This wasn't a standalone study, so this was part of a much wider, as Vicky mentioned, study that we call Badger.

    So building an evidence base for the use of advice and guidance across the primary secondary care interface.

    So as well as interviewing primary care clinicians, we also interviewed secondary care clinicians and patients and commissioners, which is part of a separate piece of published work, or hopefully published work.

    So this paper is very much focusing on understanding the clinical reasoning behind using advice and guidance from the primary care perspective.

    And following the analysis of the interviews, we came out with four sort of overarching themes which were around advice and guidance being used, dependent on clinical presentation, so acuity and complexity.

    So I think we heard from gps, quite understandably that, you know, if somebody was incredibly unwell and needed acute admission, then that would be done, and if it was a clear need for a referral, then that would be done.

    So advice and guidance was being used in these cases where it was felt that a full formalised elective referral wasn't necessary or might not be necessary.

    And it was perhaps at the sort of edge of what can be done in primary care or should be done in primary care or within the skillsets of primary care.

    But it was also being used to navigate healthcare pathways which are ever changing.

    And the other things that were sort of influencing use was previous experience.

    So clinicians who had very positive experiences were more likely to use it again.

    And that could be kind of specialty specific.

    It wasn't just a general rule.

    And it was also used in a sort of more nuanced way around validating clinical decision making and to really support patients.

    So if patients felt that they needed the input of a specialist and there was any sort of degree of uncertainty, then sometimes it was also used to provide effective reassurance to patients if there was maybe some disagreement or conflicts in the need for that referral.

    Speaker A
    00:05:56.720 - 00:06:12.480
    Yeah, and I wonder if we could just unpick some of those themes a bit further.

    So you talked about how clinicians used advice and guidance to navigate complicated healthcare pathways.

    And could you give us an idea of how that would work in practice?

    So what sort of examples would that suggest?

    Speaker B
    00:06:13.600 - 00:07:20.720
    So, I think when it comes to referral, there are obviously some very sort of objective times when a referral needs to be made.

    So if the patient is presenting with symptoms that need to be fast tracked on a T rek cancer pathway, then that's very clear.

    And then there are some other diagnoses that we know require specialist input to make.

    But sometimes, particularly if the systems around the practice are changing, so, you know, different clinics in different settings being provided by different groups, advice and guidance can just help ensure that a referral that is potentially being made is made to the right place to save time and increase efficiency.

    And, yeah, that's really quite supportive of the SPO model, isn't it, that there is a single point of access into the specialist healthcare system.

    So we did hear from clinicians that it was being used to navigate this.

    I guess the other important thing is to just contextualise the landscape that these interviews were taking place in, because these interviews happened at a bit of a crossover period, before Spiro was a thing.

    Speaker A
    00:07:21.200 - 00:07:39.920
    Yeah.

    And I guess that's one thing to mention that advice and guidance is sort of a bigger part of the policy direction for general practice in England and sort of has a more embedded use in the sort of recent GP contract.

    So do you have any thoughts about its shift towards wider use, given the work that you've been doing more broadly about advice and guidance?

    Speaker...
  • BJGP Interviews

    When women’s pain goes unheard: chronic pelvic pain and sexual violence

    03/11/2026 | 19min
    Today, we’re speaking to Cate McCarter and Amanda Williams. We’re here to discuss the research they’ve recently published here in the BJGP titled, ‘Understanding chronic pelvic pain in women survivors of sexual violence: a qualitative study’.
    Title of paper: Understanding chronic pelvic pain in women survivors of sexual violence: a qualitative study
    Available at: https://doi.org/10.3399/BJGP.2026.0057
    Chronic pelvic pain (CPP) is common and can be difficult to treat. Some women with CPP are survivors of sexual violence. How such women understood their pain was strongly influenced by feeling ignored by doctors and shamed by both CPP and sexual violence. According to women in our study, a ‘good enough’ response from GPs involved being seen as a whole person, being asked about sexual violence, pain being adequately investigated, and the GP acknowledging what is not understood about CPP and sexual violence. This allowed the negotiation of a pain explanation that validated the woman’s experience and integrated her social context with medical results, delivered with empathy and understanding.
    Transcript
    This transcript was generated using AI and has not been reviewed for accuracy. Please be aware it may contain errors or omissions.
    Speaker A
    00:00:00.240 - 00:00:56.560
    Hi, and welcome to BJGP Interviews.

    I'm Nada Khan and I'm the senior research editor here at the bjgp.

    Thanks for listening to this podcast today.

    In today's episode, we're Speaking to Kate McCarter, a clinical psychologist and Professor Amanda Williams.

    Amanda is emeritus professor of Clinical Health psychology based at ucl, and we're here to discuss the paper that they've recently published here in the bjgp, which is titled Understanding Chronic Pelvic Pain in Women Survivors of Sexual Violence A Qualitative Study.

    So, Kate, I think I'll start with you.

    And we were talking just about, you know, how important this work is, and perhaps we could just start by talking about why you wanted to explore the experiences of women with chronic pelvic pain who have also experienced sexual violence.

    What did you feel was missing from what we already know in this area?

    Speaker B
    00:00:57.650 - 00:02:15.360
    Yeah, I suppose the.

    I approached this research topic with anecdotal evidence, having worked with survivors of nursing and sexual violence for about 10 years before I started researching this.

    Just anecdotal evidence that lots of women also lived with chronic pelvic pain.

    And I didn't, you know, I hadn't any thoughts about the association really, or whether it was causal or what, but I just noticed that the women I was supporting before training as a psychologist, they were living with chronic pelvic pain, and a lot of them had found it very difficult to seek health care and to receive health care for that.

    So I just started speaking to Amanda about that, and from our conversations, we started thinking about the meaning of pain and how there's an established association within the literature about chronic pain, chronic pelvic pain after sexual violence.

    But what's the meaning of that for the women who live with it?

    That felt missing.

    And because meaning, personal meaning, is so key to understanding a personal lived experience of pain, it felt like a gap that we could begin to address by asking women, how do you make sense of the pain that you're living with?

    Came from there, really.

    Speaker A
    00:02:15.440 - 00:02:24.400
    And your background is as a clinical psychologist.

    So interpreting what pain means is quite a personal thing for a lot of women, isn't it?

    I guess.

    Speaker B
    00:02:24.480 - 00:03:23.180
    Yeah, absolutely.

    Yeah.

    Is very personal and.

    And complex as well.

    The.

    The attempts to understand exactly what pain means to a woman is, you know, you take into account those experiences of trauma very often, but not always, and you take into account the social context and what's going on around them, how sort of how they've come to be in the situation they're in.

    So, yeah, it is Highly personal and effective treatment can't really start until that's understood because the way that a woman will approach her attempts to seek health care is very much led by how she makes sense of it.

    So if she's.

    Some of the women in the study linked it to surviving sexual violence, then the meaning is wrapped up in that.

    Has she disclosed that to her healthcare provider?

    Does she feel able to.

    It's an incredibly difficult thing to talk about.

    Has she been asked?

    So, so yeah, very personal, absolutely.

    Speaker C
    00:03:23.820 - 00:04:12.840
    And I think often sort of co created in the encounter with healthcare professionals and that can go either way and in the paper are examples of both.

    But women are looking for information and understanding to incorporate into the meanings of pain and that doesn't always happen.

    Or they get multiple different accounts which are incompatible.

    People really struggle.

    I mean, I've worked in pain for 35 years and I hear this in all sorts of pain, but I think particularly where there isn't anything very definite, no tissue damage to identify, nothing to show for it, as it were.

    Speaker A
    00:04:12.920 - 00:04:36.579
    And this is a really sensitive area.

    And you interviewed 10 women about both their pain and their experiences of sex, sexual violence.

    I just wanted to touch on how you approached these conversations and how you learned from listening to women in this way, sort of taking both of these things into account.

    And we'll go a little bit more in depth into the themes that you discovered.

    But yeah, just as a sort of overview.

    I wonder if you wanted to comment on that.

    Speaker B
    00:04:36.739 - 00:05:54.960
    I suppose it started with I believe that you've been sexually assaulted.

    There was no question about that.

    And I think the reason I say that is because that's.

    That's often disbelieved or dismissed or minimized by anyone.

    It's not specific to healthcare at.

    By anyone that a woman tells about her experience.

    So I think it started from that even before we had a conversation.

    The advertisement, the information sheet about consenting into the study was.

    I tried to make it as validating as possible.

    It was an opportunity to talk in depth about a topic, topics that are taboo, that are not spoken about, that are shamefully hidden.

    And I think giving women the opportunity in a space where they felt believed meant that women perhaps relaxed into the conversation as we got talking.

    I think also it helped that it was a semi structured interview so I was very much able to follow where that woman was going.

    But I think also the women were so motivated to talk to me, they really encouraged me to publish.

    I wasn't.

    I don't love writing.

    Amanda's very good at writing.

    I don't love it, but I really wanted to do it for them.

    I said I would and therefore I did.

    Speaker A
    00:05:55.360 - 00:06:05.120
    And one of your main themes was attempts at silencing women.

    What did women mean by that and what were they experiencing when they tried to get healthcare for their pain?

    Speaker B
    00:06:05.600 - 00:07:28.130
    So this, this was a finding that really fitted with both experiences of pain and of surviving sexual violence.

    And women were talking about being actively told not to talk about those things.

    So sometimes they're disclosed to a family member and they'd been told, I don't believe you, or don't talk about that.

    That's just something that women have to go through.

    But also, unfortunately, some encounters with health care professionals as well.

    So not being believed, not being asked as well.

    That was a really significant part of some of the women's narratives, that if you don't ask, then I won't tell you.

    And that's, that's not a new finding that's fairly established within primary care.

    The women in this study really just backed up that finding that women want to be asked that it's, it facilitates disclosure of difficult experiences, sexual violence being one of those.

    So if they'd, if they'd been asked, then they were more likely to disclose.

    But, yeah, it's the responses to that disclosure that were, that was silencing and that fitting within a societal context of minimizing sexual violence, of minimizing particularly women's pain, particularly in the pelvic area.

    And the message of just get on with it, really.

    Speaker A
    00:07:28.850 - 00:07:44.440
    And I wonder just a little bit, I mean, that comes through quite strongly, that experience of not being believed or of having pain attributed to mental health problems.

    But why do you have any thoughts, either of you, about why that happens, particularly with chronic pelvic pain in women?

    Speaker B
    00:07:44.840 -...
  • BJGP Interviews

    From barriers to belonging - Black researchers in academic primary care

    27/10/2026 | 16min
    Today, we’re speaking to Dr Rupinder Bajwa, a Research Fellow based in the centre for Academic Primary Care at the University of Nottingham.
    Title of paper: Unpacking barriers to and facilitators for research leadership for Black primary care researchers: a qualitative study
    Available at: https://doi.org/10.3399/BJGP.2026.0175
    Researchers of Black heritage are underrepresented in primary care research leadership, and there is limited evidence on their lived experiences of why this underrepresentation exists. This study addresses this evidence gap and highlights how systemic inequities, racism, and inequitable academic practices contribute to this lack of representation. This study also presents practical enablers to improve progression and retention, such as proactive leadership, tailored career support, and increasing visibility of Black role models in academic primary care. These findings emphasise the need to foster inclusive research environments that strengthen the diversity and relevance of primary care evidence.
    Transcript
    This transcript was generated using AI and has not been reviewed for accuracy. Please be aware it may contain errors or omissions.
    Speaker A
    00:00:01.120 - 00:00:54.620
    Hi and welcome to BJGP Interviews.

    I'm Nada Khan, I'm the Senior Research editor at the BJ gp.

    And thanks very much for joining me here to listen to this podcast.

    In today's episode, we're speaking to Dr. Rupinder Bajwa.

    Rupinder is a research fellow based in the Centre for Academic Primary Care at the University of Nottingham.

    We're here to talk about the paper she's recently published in the BJGP titled Unpacking Barriers to and Facilitators for Research Leadership for Black Primary Care A Qualitative Study.

    So, hi, Rupinder, it's really great to meet to talk about this work and I wonder if we could just start by talking through what prompted you and your team to look at the experiences of black researchers in academic primary care.

    And I'm wondering what we already knew in this area and what you felt was missing from the picture.

    Speaker B
    00:00:55.260 - 00:01:34.840
    Firstly, thank you so much for having me on to talk about the work that we did so the way this sort of came about.

    So primary care serves some of the most diverse communities in the uk, but what we realised is, when you look at primary care, researchers of black heritage remain largely underrepresented, especially in more senior academic and leadership roles.

    And so because of that, we wanted to understand, well, why does this gap exist and, you know, what can we do to improve representation but also improve retention of researchers of black heritage and their career progression as well?

    Speaker A
    00:01:34.920 - 00:01:43.320
    And you spoke to people from a black background, is that right?

    So talk us through just who you discussed this project with and how you got those.

    Speaker B
    00:01:43.640 - 00:03:01.100
    Yeah.

    So to start with the project team itself, there's myself, I'm a researcher of South Asian heritage.

    We had Adwa and Ralph, who are researchers of black heritage.

    Manpreet Rains is a researcher of South Asian heritage.

    We have Professor Joe Kai on the team, who is also of Asian Heritage.

    And we had Professor Christian Mallon on the team as well, who is a senior leader at the School for primary Care research.

    And so we had sort of that diversity within the study team.

    We predominantly wanted to speak to researchers of black heritage who are working in academic primary care across all levels, so from junior up to senior.

    And we also spoke to leaders of departments where, you know, they're leading academic primary care departments as well.

    And we, you know, really wanted to explore what, especially with the researchers, you know, barriers that they've experienced or barriers that they know of as well as what's gone well for them as well, you know, for their progression opportunities that they've had, but also, you know, what their thoughts and feelings were around the current level of representation and what could be done and with leaders as well.

    We sort of spoke about some of the barriers, but also some of the work that might be going on on to address some of these barriers as well.

    Speaker A
    00:03:01.340 - 00:03:25.340
    Just the introduction to your paper and work that's been done more widely in this area.

    We do know that the underrepresentation of researchers of black heritage drops off, particularly as sort of more senior levels of academia.

    And I wonder what you heard from the experiences of researchers as they move through their careers and why does that progression seem to become more difficult?

    Speaker B
    00:03:26.280 - 00:04:51.480
    Yes.

    So a lot of what we found in the project isn't just an academic primary care problem.

    I'll start with that.

    It does speak to wider challenges across academia.

    So when you look at academia as a whole, I think it's around 1% of professors are of black heritage.

    So that's quite a small number.

    Speaking to researchers around their progression.

    We wanted to understand what some of those challenges are.

    And what came through was there are a lot of structural and systemic barriers that continue.

    So structural and systemic racism is one key challenge.

    And when we were speaking to researchers, what this looked like.

    You know, it was more, it could be subtle microaggressions being passed up for opportunities, stereotypes, but also sometimes the academic culture could be quite exclusionary and researchers found that it was sometimes difficult to find opportunities.

    There was limited access to some development opportunities as well.

    And especially for a junior level, sort of the short term contracts and the funding insecurity made that progression difficult.

    And for those who were sort of mid career researchers and thinking about the next steps, it was, you know, well, what does that look like?

    What support is available?

    Is there any support available?

    And there was challenges around that is finding adequate support, adequate mentorship and sponsorship as well.

    Speaker A
    00:04:51.810 - 00:05:10.690
    And you know, you're talking about these structural and interpersonal barriers as well.

    But I wonder how that impacts things like academic funding or recognition and how that's distributed.

    Did they talk about barriers to getting funding or grants and recognition for the work they were doing?

    Speaker B
    00:05:10.770 - 00:06:02.430
    Yeah, so this was a, this was a concern as well that came up and researchers were keen to highlight that, you know, this is a challenge across the board in terms of research funding.

    A lot has changed in the last few years.

    Pools of funding have got smaller, but it seems to be there's additional challenges involved for minoritised researchers in terms of how to get that funding, how to apply for that funding, you know, how to position yourself for that Funding, unless you know it, you don't know it.

    And it can be even more challenging if you're a minoritised researcher where you may be starting off on a slightly different footing, coming into the space.

    And that can make it really difficult for funding.

    But more recently, I know NIHR and funding bodies are now looking at this and making proactive steps to address that, which is really positive.

    Speaker A
    00:06:02.910 - 00:06:18.030
    And one thing that really struck me was the difficulty that some people felt in speaking up about discrimination.

    So what did the people that you spoke to tell you about raising concerns?

    And I wonder whether that says something about sort of the culture within academic institutions as well.

    Speaker B
    00:06:18.400 - 00:07:15.700
    Yeah, this came up across levels as well.

    So it wasn't just junior researchers, but senior researchers reflected on their experiences as junior researchers as well.

    And there was a concern around the impact that raising issues could have on their careers, but also concerns around actually, will anything be done about it?

    If I raise it, what's going to come out of this?

    And so people might not report it then if they a, feel it will impact their career and impact their trajectory.

    But then also if they feel that actually, you know, I don't really have faith that the system will address this or anything will change that then will leave them feeling like actually it's not worth reporting it.

    And that in itself is challenging because if you've been, you know, if you've experienced that, you should be able to go somewhere that's impartial and that will take your experiences seriously and look into it and address that.

    Speaker A
    00:07:16.190 - 00:07:31.070
    And you mentioned that when you conducted this study, you also wanted to look at things that helped people to stay and progress.

    So I wonder if you could talk through just some of these different areas because there...
  • BJGP Interviews

    Recurrent UTIs: which non-antibiotic approaches actually work?

    20/10/2026 | 19min
    Today, we’re speaking to Professor Miriam Santer, a GP in Dorset and Professor of Primary Care Research based at the University of Southampton.
    Title of paper: Non-antibiotic interventions to prevent recurrent urinary tract infections in women: overview of systematic reviews of randomised controlled trials

    DOI: https://doi.org/10.3399/BJGP.2026.0055

    Recurrent urinary tract infection (UTI) is very common and defined as two or more UTIs in the last six months or three or more UTIs in the last 12 months. Long-term antibiotic prophylaxis is widely used but other preventative strategies have been suggested. This overview of systematic reviews found good evidence for some treatments but identified unresolved questions such as treatment adherence for vaginal oestrogen, questions about long-term use for methenamine hippurate and optimal dosage for cranberry. Increased fluid intake has been shown to be of benefit for women drinking less than 1.5 litres at baseline but is without robust evidence in other groups. The evidence base is still developing for other treatments, such as vaccines.
    Transcript
    This transcript was generated using AI and has not been reviewed for accuracy. Please be aware it may contain errors or omissions.
    Speaker A
    00:00:00.560 - 00:00:55.830
    Hi and welcome today to BJJP interviews.

    I'm Nada Khan and I'm the Senior Research editor for the bjgp.

    In today's episode, we're talking to Professor Miriam Santer, a GP in Dorset and Professor of Primary care research based at the University of Southampton.

    We're here to discuss the recent paper she's published here in the BJJP titled Non Antibiotic Interventions to Prevent Recurrent Urinary Tract Infections in Women.

    An Overview of Systematic Reviews of Randomized Controlled Trials.

    So, hi Miriam, it's nice to see you again.

    And I suppose to start with, it's worth acknowledging that recurrent UTIs are something that we see incredibly often as GPs, but they can also have a really big impact on women's lives and I guess I just wanted to go through what prompted you to take this angle in this review and think about non antibiotic options for preventing them?

    Speaker B
    00:00:56.520 - 00:02:38.580
    Well, it was exactly that, that I had a colleague, a non clinical colleague who had recurrent UTI and I guess I hadn't really appreciated the massive impact that they had in terms of, you know, keeping, being ill, keeping missing work, everything else.

    And it did make me think again about my own practice, whether I really manage recurrent UTI or whether I just manage it as a series of one off events.

    So it made me think about my own practice.

    And then also the reason we looked at non antibiotic options was because the Primary Care Research Centre in Southampton where I work, we do a lot of work on infections and on antimicrobial stewardship and we were aware that prophylactic antibiotics tend to be quite well used and also series of one off antibiotic episodes are quite well used but that the non antibiotic interventions, we felt they were less well used and just wanted to know the evidence behind it.

    Apart from doing infections research, we also do a lot of research on how to support people self manage long term conditions and we thought we could make a brilliant resource or online intervention to help people prevent urinary tract infection.

    And as part of that we just wanted to know a bit more about the evidence based and in some ways we were a little disappointed that there wasn't much evidence for some of the very commonly advised things, but also surprised that for some things like methenamine and vaginal estrogen, actually the evidence base is, is pretty well established now.

    So it was interesting.

    Speaker A
    00:02:38.900 - 00:03:04.080
    Yeah.

    And as you said, there's a huge number of things that women are told might help prevent recurrent UTIs and this was an umbrella review that brought together evidence from 27 systematic reviews.

    But let's just talk through what.

    So you mentioned about vaginal oestrogen, because this seems to be one of the clearest messages from the review.

    Talk us through what you found and how strong is the evidence here?

    Speaker B
    00:03:04.480 - 00:04:07.360
    So there were seven systematic reviews covering vaginal estrogen and they were pretty positive and especially the most recent one.

    To be fair, most of the evidence is in post menopausal women, but the NICE guideline changed in 2024 to say perimenopausal and postmenopausal, because there's awareness in the rest of the menopause literature that actually genital urinary symptoms in menopause are often do present before menopause.

    So it's a slightly confusing message.

    The evidence base for prevention of UTIs is postmenopausal, but the guidelines are perimenopausal and postmenopausal.

    But the evidence is pretty strong.

    It's been amassing over a number of years.

    Seven systematic reviews have been positive about it.

    Unlike systemic oestrogen, where systematic reviews have been pretty conclusive that systemic estrogen doesn't make a difference in preventing recurrence.

    But of course, women can take both at the same time if they need to.

    Speaker A
    00:04:07.520 - 00:04:21.750
    And one thing I found really interesting was that there was particularly low uptake of vaginal estrogen in more deprived areas.

    Do you think that there's something driving that and what can we do to try to prevent that sort of inequity in access?

    Speaker B
    00:04:21.990 - 00:05:59.500
    And it's tempting to say more research needed.

    And that was something we found in the literature, that there's a suggestion that vagina strings are less used in the UK than elsewhere.

    They're less used in areas of greater socioeconomic deprivation.

    And also it's not very well understood whether it's a prescribing issue or whether it's an uptake and adherence or acceptability issue.

    There's.

    So for prescribers, there's some things that are off putting.

    So I don't really understand why vagina are not licensed for prevention of uti, given the evidence base for women.

    It's a number of other things.

    Sometimes, you know, not having had a sufficiently informed discussion about all the different types, you know, gel cream, pessaries, and sometimes it's also that the patient information leaflet that comes with the packet describes it as hrt, where it's really very little of it is systemically absorbed.

    So it, it is, it's safer than hrt.

    I mean, of course HRT is Pretty safe.

    Vaginal estrogen is even safer.

    But that message doesn't always get across.

    And then also maybe it's because the information leaflet and all the other information tends to focus on genital urine symptoms of the menopause that people don't necessarily link it in their minds.

    And I'm talking about prescribers as well as women with preventing UTI and maybe just don't keep using it long enough.

    So more research needed.

    But I think there's a number of barriers to uptake regarding vaginal estrogen and.

    Speaker A
    00:05:59.500 - 00:06:22.180
    I can think of a lot of conversations I've had with women with recurrent UTIs and suggesting vaginal estrogen and often they're quite surprised but quite happy that I'm suggesting something that could work.

    So I think there is a bit of a information asymmetry there between what some prescribers are doing, maybe people who are really used to prescribing these things and patients as well.

    Speaker B
    00:06:22.340 - 00:06:41.460
    And I've also certainly met a few women who said, oh, was I meant to keep using that?

    They don't necessarily see it as a, as something they need to take in the long term to keep preventing it, you know, which is.

    And for something which you're only doing twice a week, that is a slightly challenging behavior to keep remembering to use it.

    Speaker A
    00:06:41.790 - 00:06:52.350
    And I guess one other thing that you also found really good evidence for was methanomine.

    Talk us through how we should be thinking about methanamine in relation to long term prophylaxis as well.

    Speaker B
    00:06:52.670 - 00:07:29.200
    So methenamine has also made it into the nice guideline on preventing recurrent uti.

    And I think I might have forgotten to say so that's anyone who's had two UTIs in six months or three UTIs in 12 months.

    And the evidence is pretty good for methenamine as well as vaginase drinks.

    As someone who hasn't responded to basic lifestyle advice, we might come on to that.

    The evidence is a little bit poor, but it's still suggested that you discuss lifestyle advice first.

    Should, if they're perimenopausal or menopausal, consider vaginal estrogen, but at all ages consider methenamine.

    Speaker A
    00:07:29.760 - 00:07:39.680
    Interesting.

    And do you think that I don't know if there's any evidence in these reviews about how they're used or whether they're underused or do you think gps are confident in prescribing these?

    Speaker B
    00:07:40.310 -...
  • BJGP Interviews

    Local incentives and general practice: what does the evidence show?

    13/10/2026 | 20min
    Today, we’re speaking to Matt Conroy. Matt is a PhD fellow at the University of Manchester and also works for NHS Greater Manchester (ICB) as the Head of Primary Care Intelligence.
    Title of paper: Impact of local enhanced incentive schemes on the performance of general practices within the United Kingdom: a systematic review
    Available at: https://doi.org/10.3399/BJGP.2025.0377
    Most local commissioning bodies in England, known as Integrated Care Boards (ICBs), have developed their own additional local pay-for-performance (P4P) incentive schemes alongside the Quality and Outcomes Framework (QOF). To our knowledge this is the first review to date to summarise existing evidence on the scope and effectiveness of local incentive schemes implemented in general practice in the UK with a focus on the indicators and their alignment with national schemes.
    Transcript
    This transcript was generated using AI and has not been reviewed for accuracy. Please be aware it may contain errors or omissions.
    Speaker A
    00:00:00.480 - 00:01:01.140
    Hi and welcome to BJGP Interviews.

    I'm Nada Khan and I'm the Senior Research Editor here at the bjgp.

    Thanks for taking the time today to listen to this podcast.

    Today we're talking to Matt Conroy.

    Matt is a PhD fellow based at the University of Manchester and he also works for NHS Greater Manchester ICB as the Head of Primary Care Intelligence.

    We're here to talk about the paper he's recently published in the bjgp, which is titled the Impact of Local Enhanced Incentive Schemes on the Performance of General Practices within the United A Systematic Review.

    So, hi, Matt, it's really nice to meet you and to talk about this work and I wonder if, just to start with, if you could explain a bit about what we mean by local incentive schemes in general practice and why you wanted to look at them, and I wonder if you wanted to draw a little bit on your additional role working for the Greater Manchester ICB as well here.

    Speaker B
    00:01:01.220 - 00:01:54.400
    Thanks.

    I guess by a local deep incentive scheme, we mean something that's kind of locally designed or locally commissioned within a ICB footprint to try and address any particular population health challenges or local nuances that go over and above national policy, things like the Quality and Outcomes Framework.

    I guess what was really insightful for us through doing this piece of work was actually through an FOI that we undertook.

    Like 90, 98% of ICBs actually have their own local gene for incentive schemes, but we only identified 17 schemes through the published literature, the last one being from 2018.

    So getting on for 10 years ago, and the fact that we know that so many ICVs are doing these things, but there's not the evidence body there, there's not the learning and sharing of best practice to really inform policy and help ICVs all try and address their local challenges.

    Speaker A
    00:01:55.210 - 00:02:10.650
    Yeah.

    And you've mentioned qof and I guess a lot of people are really familiar with qof, and as you mentioned, there are lots of local schemes sitting alongside it.

    And I wonder if you have an idea of just what sort of things they're trying to incentivize, just from sort of the background to your work.

    Speaker B
    00:02:11.210 - 00:04:48.850
    Yes.

    So, as part of my day job, I help design and deliver the local GP incentive scheme in Greater Manchester.

    It's roughly valued about £17 million for this year.

    And I think what we try to do is use QOF as a bit of a body of evidence, but also look at a lot of our local and national data to really highlight where we think we can make a difference with these local incentive schemes.

    So, for the 26, 27 financial year, we've done a piece of work to really home in on CBD and diabetes as one area, respiratory as another area, elective care.

    So we can get the interface between primary and secondary care and also antimicrobial stewardship.

    I think one of the things that's really fleshed out from that is the impact of non attenders on things like qof.

    So through qaff, if patients have two or one invites seven days apart, they automatically get exception reported if they don't necessarily attend.

    But what we found through our local data is actually there's a really strong link between those people and actually poorer CBD control and wide use of healthcare systems.

    So.

    So through our local GP insentive scheme, we've really designed almost a narrow cohort that looks at people's individual disease control, looking at things like blood pressure, HbA1c, but also where people haven't attended a review in more than 18 months.

    So really trying to hone in on specific cohort, acknowledging that those people are really difficult to engage with by proxy.

    The fact that they've had two invites and not responded.

    But actually through having a local GP incentive scheme that really highlights these as a specific target cohort group and having dedicated funding alongside it, we can see that from our QOF data, we've had a reduction in exception reporting and actually it's led to these people being targeted and then we can see slow improvements in overall disease control.

    So whilst it's being funneled through the local GP incentive scheme, there's this wider spillover effect in things like QOF as well.

    I think that's something that we're looking to evaluate in particular and really draw out, actually, not to say that it's easy to do this exceptional reporting and we know that patients are difficult to engage with, but actually by having a really dedicated piece of work, targets these patients with the body of evidence that these are the people who are more likely to not attend their yearly GP review, but are more likely to end up using emergency care services at that point of contact, that if there's dedicated funding and almost a dedicated cohort, to say these are the people that, as an icb, we've agreed on that we really need to focus on that we can see that those improvements are being yielded and that that is actually having a secondary impact of increasing coif achievement as well.

    Speaker A
    00:04:49.010 - 00:05:03.310
    Yeah.

    So really important work, I guess, being done in local area and this review tried to bring together all of the existing evidence on this, on these different schemes.

    So what did you find overall in your, in your review?

    Speaker B
    00:05:03.550 - 00:07:48.730
    So we found overall that there was 17 schemes that have been reviewed.

    Of those there was a range of different indicator types, the most of them aligning to the existing indicator types of quaff where they have a lower and upper threshold and achievement scales based on fixed cohort and payment alongside that, which isn't surprising.

    And I think what surprised me is that so many of the schemes almost piggybacked off QUAFF and just gave more money for existing cough indicators, which was quite surprising in a sense of well, if quaff is already there and as well bodied there was almost that assumption, well, if we provide more money that we're going to get greater achievement on the same indicators that's already there.

    I think this is the part of the, the push and pull of incentive schemes is that we're all aware that general practice has finite capacity and finite resource and there's almost an assumption that by providing more money you're going to get more outcomes.

    And it's a bit crude but the analogies, it's a bit like whack a mole and that if you try and do something over here then implicitly means that something there isn't the time and dedicated effort to do something else around the system.

    I think that's the real challenge with designing these schemes is that acknowledging that where there's already work that's gone in, but how do you address your local challenges and populations and that part of this might be the acceptance, that part of the money is just to give practices the time and the headspace and the workforce to deliver some of this.

    I think that's one of the things that we've found really locally within our scheme that when we've scaled it up in some areas quite drastically in the first couple of years, you might not see the achievement that you want because there's a lot of time to get around these schemes, to embed them and really employ the workforce to actually start to deliver them.

    I think the other thing that surprised me is that how little of them actually had an inequalities focus.

    I think that's partly down to the access to data that's available.

    I think through undertaking the literature review in a lot of cases people were just using aggregated EMIS extracts that just had a single denominator or numerator for an indicator.

    And that's something that I think we're really keen to explore throughout the rest of my PhD and that how can we really apply a, a rigorous inequalities lens to some of this and looking at tools like the index of disparity as a way of helping us understand are we in a position where it might look on the surface like achievements going up?

    And that's great, but is that because we sweep in generalization, are we actually targeting the white British affluent worried well and actually
Mais podcasts de Ciência
Sobre BJGP Interviews
Listen to BJGP Interviews for the latest updates on primary care and general practice research. Hear from researchers and clinicians who will update and guide you to the best practice. We all want to deliver better care to patients and improve health through better research and its translation into practice and policy. The BJGP is a leading international journal of primary care with the aim to serve the primary care community. Whether you are a general practitioner or a nurse, a researcher, we publish a full range of research studies from RCTs to the best qualitative literature on primary care. In addition, we publish editorials, articles on the clinical practice, and in-depth analysis of the topics that matter. We are inclusive and determined to serve the primary care community. BJGP Interviews brings all these articles to you through conversations with world-leading experts. The BJGP is the journal of the UK's Royal College of General Practitioners (RCGP). The RCGP grant full editorial independence to the BJGP and the views published in the BJGP do not necessarily represent those of the College. For all the latest research, editorials and clinical practice articles visit BJGP.org (https://bjgp.org). If you want all the podcast shownotes plus the latest comment and opinion on primary care and general practice then visit BJGP Life (https://www.bjgplife.com).
Site de podcast

Ouça BJGP Interviews, InfectoCast e muitos outros podcasts de todo o mundo com o aplicativo o radio.net

Obtenha o aplicativo gratuito radio.net

  • Guardar rádios e podcasts favoritos
  • Transmissão via Wi-Fi ou Bluetooth
  • Carplay & Android Audo compatìvel
  • E ainda mais funções